Security
SciSparc Ltd. Ordinary Shares · SPRC
SPRCNASDAQCommon stockCurrentCIK 1611746Updated Oct 8, 2026
Name history
SciSparc Ltd./ADR · through Aug 27, 2021Therapix Biosciences Ltd. · through Jan 28, 2021
SPRC price & chart
Loading TradingView…
NASDAQ:SPRC on TradingView ↗About the company
The Company, through its majority-owned subsidiary NeuroThera, engages in clinical-stage pharmaceutical developments. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company, together with its majority-owned subsidiary NeuroThera, is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer’s disease and agitation; and SCI- 210 for the treatment of autism spectrum disorder and status epilepticus. The Company, through NeuroThera, also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace.
In the news
SciSparc: Subsidiary NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S&P 500 company ↗
Recent filings
Show 5 more recent filings
Financials
FY 2024 · USDSource
Source
Source
Source
cash flow · annual statements
| Line item | Q2 2018 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||
| Profit or LossUSD | -1,214,000Source | -7,472,000Source | -5,883,000Source | -2,592,000Source | -5,789,000Source |
| Additional Financial Items | |||||
| AdjustmentsForDecreaseIncreaseInTradeAccountReceivableUSD | -50,000Source | 12,000Source | 55,000Source | 3,000Source | 170,000Source |
| AdjustmentsForIncreaseDecreaseInTradeAccountPayableUSD | -101,000Source | 25,000Source | -397,000Source | — | 353,000Source |
| AdjustmentsForSharebasedPaymentsUSD | 138,000Source | 569,000Source | 196,000Source | — | 43,000Source |
| GeneralAndAdministrativeExpenseUSD | 1,000,000Source | 4,526,000Source | 5,031,000Source | 6,509,000Source | 3,778,000Source |
| InterestPaidClassifiedAsFinancingActivitiesUSD | — | 8,000Source | 7,000Source | — | — |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesUSD | — | 54,000Source | 47,000Source | — | — |
| ProceedsFromBorrowingsClassifiedAsFinancingActivitiesUSD | — | — | — | 9,005,000Source | 7,699,000Source |
| ProceedsFromIssuingSharesUSD | — | 6,255,000Source | — | — | — |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesUSD | — | — | — | 4,861,000Source | — |
income statement · annual statements
| Line item | Q2 2022 | Q2 2018 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Cost of Goods and Services Sold | — | — | —Source | —Source | —Source | — |
| Selling, General and Administrative ExpenseUSD | — | — | — | 5,031,000Source | 6,509,000Source | 3,778,000Source |
| Total RevenueUSD | — | — | 1,306,000Source | 2,879,000Source | 1,347,000Source | — |
| Additional Financial Items | ||||||
| ApplicableTaxRatenumber | — | — | — | 0.23Source | 0.23Source | 0.23Source |
| BasicEarningsLossPerShareUSD per share | — | — | 26.94Source | 14.43Source | — | 2.83Source |
| DilutedEarningsLossPerShareUSD per share | — | — | 26.94Source | 14.43Source | — | — |
| EmployeeBenefitsExpenseUSD | — | — | 106,000Source | 105,000Source | 115,000Source | 98,000Source |
| FinanceCostsUSD | — | 1,000Source | 353,000Source | 1,055,000Source | 2,014,000Source | 21,000Source |
| FinanceIncomeUSD | — | 437,000Source | 612,000Source | 2,219,000Source | 7,832,000Source | — |
| GeneralAndAdministrativeExpenseUSD | — | 1,000,000Source | 4,526,000Source | 5,031,000Source | 6,509,000Source | 3,778,000Source |
| GrossProfitUSD | 10,210,000Source | — | 506,000Source | 2,196,000Source | 1,025,000Source | — |
| ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillUSD | — | — | 1,344,000Source | — | — | — |
| IncomeTaxExpenseContinuingOperationsUSD | — | — | -14,000Source | 22,000Source | 14,000Source | — |
| OtherIncomeUSD | — | — | 1,270,000Source | — | — | — |
| OtherOperatingIncomeExpenseUSD | — | — | — | — | -109,000Source | — |
| ProfitLossAttributableToNoncontrollingInterestsUSD | — | — | -1,188,000Source | -761,000Source | — | — |
| ProfitLossAttributableToOwnersOfParentUSD | — | — | -6,284,000Source | -5,122,000Source | 2,592,000Source | 5,789,000Source |
| ProfitLossBeforeTaxUSD | — | — | -7,486,000Source | -5,861,000Source | -2,578,000Source | — |
| ProfitLossFromOperatingActivitiesUSD | — | -1,650,000Source | -7,316,000Source | -6,815,000Source | -8,287,000Source | -5,768,000Source |
| ResearchAndDevelopmentExpenseUSD | — | 650,000Source | 1,707,000Source | 1,641,000Source | 2,803,000Source | 1,990,000Source |
| ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodUSD | — | — | -429,000Source | -210,000Source | -109,000Source | — |
Offerings
Registration 333-293533
Filing attachments
ea030872201ex99-1.htm · 6-K · 2026-10-15
Exhibit 99.1 SciSparc Announces Transformation into Agentic AI-Powered Technologies, Including Cybersecurity and Finance Technologies TEL AVIV, Israel, Oct. 15, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that it will shift its strategic focus toward Agentic AI-powered technologies, including cybersecurity and finance technologies. Building on its previously announced decision on July 27, 2026 to target the Agentic AI market and the announc…
Read attachment ↗ea030793702ex99-1.htm · 6-K · 2026-10-07
Exhibit 99.1 SciSparc: Subsidiary NeuroThera Labs’ CliniQuantum Reports Successful Quantum-Enabled Analysis of Billions of Gene Combinations Using Real-World Clinical Data on an S&P 500 Company’s Quantum Architecture TEL AVIV, Israel, Oct. 07, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) (“NeuroThera”), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous sys…
Read attachment ↗ea030686801ex99-1.htm · 6-K · 2026-09-30
Exhibit 99.1 SCISPARC LTD. INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2026 UNAUDITED INDEX Page Consolidated Statements of Financial Position 2-3 Consolidated Statements of Profit or Loss and Other Comprehensive Loss 4 Consolidated Statements of Changes in Equity (Deficit) 5-6 Consolidated Statements of Cash Flows …
Read attachment ↗ea030686801ex99-2.htm · 6-K · 2026-09-30
Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of our financial condition and results of operations provides information that we believe to be relevant to an assessment and understanding of our results of operations and financial condition for the periods described. This discussion should be read in conjunction with our interim consolidated financial statements and the notes to such financial statements,…
Read attachment ↗ea030637702ex99-1.htm · 6-K · 2026-09-24
Exhibit 99.1 SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations The U.S. patent applications cover proprietary combinations of NeuroThera’s PEA technology with LSD, ketamine and ibogaine for potential therapeutic applications, including mental health disorders, such as depression and PTSD as well as substance use disorders TEL AVIV, Israel, Sept. 23, 2026 (GLOBE NEWSWIRE) -- SciS…
Read attachment ↗ea030438401ex99-1.htm · 6-K · 2026-09-02
Exhibit 99.1 SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI-210 Autism Clinical Trial TEL AVIV, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, continued advancement in participant enrollment for the clinical trial assessi…
Read attachment ↗